10-QPeriod: Q3 FY2009

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2009

Filed November 4, 2009For Securities:ALNY

Summary

This 10-Q filing from ALNYLAM PHARMACEUTICALS, INC. for the period ending September 30, 2009, details the company's financial position and operational results during the third quarter and the first nine months of the year. Investors should note the significant net loss reported, consistent with a company in the development stage of the pharmaceutical industry. While revenue figures are not explicitly detailed in the provided table of contents, the focus on 'Results of Operations' suggests ongoing research and development activities, which are typical drivers of expenses and losses at this stage. The company's balance sheet reflects its assets and liabilities as of September 30, 2009, compared to the end of the prior fiscal year. The statements of cash flows provide insight into the company's liquidity and how it is using its cash, particularly important for understanding its ability to fund its ongoing research and development projects. Investors should pay close attention to the 'Management's Discussion and Analysis' and 'Risk Factors' sections for a deeper understanding of the company's strategic direction, financial condition, and the inherent risks associated with pharmaceutical development.

Financial Highlights

22 data points
Beta

Revenue

$24.25M

Net Income

-$9.21M

-38.0% Net Margin

Cash & Equivalents

$98.09M

Free Cash Flow

-$21.32M

Financial Statements
Beta
Revenue$24.25M
R&D Expenses$23.22M
Operating Expenses$33.90M
Operating Income-$9.65M
Net Income-$9.21M

Key Highlights

  • 1The filing includes unaudited condensed consolidated financial statements, providing a snapshot of Alnylam Pharmaceuticals' financial health.
  • 2Key financial statements cover the balance sheets, statements of operations and comprehensive loss, and cash flows for the nine-month periods ending September 30, 2009, and the comparative prior year periods.
  • 3Management's Discussion and Analysis (MD&A) section is crucial for understanding the operational results and financial condition, offering management's perspective on performance.
  • 4The company reported a net loss, which is typical for biopharmaceutical companies investing heavily in research and development.
  • 5Disclosures on market risk are provided, outlining potential impacts of market fluctuations on the company's financial performance.
  • 6Risk factors are detailed, giving investors insight into the potential challenges and uncertainties Alnylam faces in its business operations and product development.
  • 7The filing includes information on legal proceedings, which could have a material impact on the company's financial standing.

Frequently Asked Questions

Based on the information typically presented in a 10-Q, Alnylam Pharmaceuticals reported a net loss for the nine months ended September 30, 2009. This is common for companies in the biopharmaceutical sector that are heavily invested in research and development.

The 'Risk Factors' section (Item 1A) of the 10-Q would detail these. Common risks for companies at this stage include clinical trial failures, regulatory hurdles, competition, intellectual property issues, and the need for significant future funding for research and commercialization.

The 'Condensed Consolidated Statements of Cash Flows' for the nine months ended September 30, 2009, will provide details on cash generated from or used in operating, investing, and financing activities. Investors should examine this to understand how the company is funding its operations and development pipeline.

This section (Item 2) is vital as it offers management's qualitative insights into the company's financial performance, liquidity, capital resources, and future outlook. It helps investors understand the context behind the numbers and management's strategies.